| Ytd | -54.82% | |
| 1y | -47.51% |
| Open | 0.36 | Prev Close | 0.39 | Low | 0.32 | High | 0.36 | Mkt Cap | 7.23M |
| Vol | 1.17M | Avg Vol | 1.27M | EPS | -2.00 | P/E | N/A | Forward P/E | -0.87 |
| Beta | 1.13 | Short Ratio | 0.43 | Inst. Own | 23.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 06-05 | Earning | 08-27 | 50-d Avg | 0.60 | 200-d Avg | 0.80 | 1yr Est | 3.00 |
TRIB News
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
- Milestone an important step in launching Trinovium within the global AI data center ecosystem- Dat
- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Da
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market
Trinity Biotech plc (NASDAQ:TRIB), a commercial stage biotechnology company focused on human diagnos
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage bio
Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi
Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market sessi
- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertis
Trinity Biotech (NASDAQ:TRIB) reported quarterly losses of $(0.23) per share. This is a 52.08 percen
– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and prof
TRINITY BIOTECH PLC Up to $4,352,314 American Depositary Shares representing Ordinary Shares We hav